Epidémiologie de la sclérose en plaques en France

En Europe, la France est située entre des zones à haut et bas risque de Sclérose en Plaques (SEP).Nous avons estimé la prévalence de la SEP en France au 31 octobre 2004 et l incidence entre 2000 et 2007 à partir des données de la Caisse Nationale d Assurance Maladie des Travailleurs Salariés (CNAMTS) qui assure 87 % de la population. La SEP, comme d autres maladies chroniques, fait partie des affections de longue durée (ALD). Les variations géographiques de la prévalence et de l incidence ont été analysées par un modèle Bayesien.La prévalence standardisée sur l âge était de 94,7 pour 100 000 ; 130,5 pour les femmes ; 54,8 pour les hommes. Le taux de notification de SEP (2000-2007) standardisé sur la population Européenne était de 6,8 pour 100 000 ; 9,8 parmi les femmes et 3,7 parmi les hommes. Avec le modèle Bayesien, la prévalence était plus forte au nord-est et plus faible dans la région parisienne et sur la Côte d Azur. L incidence était également plus forte au nord-est mais plus faible sur la côte atlantique et de part et d autre du Rhône.A partir des autres ALD, les comorbidités survenant avant l ALD SEP ont été étudiées. Elles étaient rares et essentiellement représentées par les troubles psychiatriques (40,2%) et le diabète (20,3%). Cette étude a été réalisée parmi une population représentative avec une seule et même méthodologie. Le modèle Bayesien prenant en compte l hétérogénéité et l auto-corrélation spatiales ne confirme pas l existence d un gradient net mais des zones à sur ou sous risque. La meilleure connaissance de l épidémiologie de la SEP permettra d avancer sur ses facteurs étiologiques.In Europe, France is located between high and low risk areas of Multiple Sclerosis (MS). We estimated the national prevalence of MS in France on 31st October 2004 and the incidence between 2000 and 2007 based on data from the Caisse Nationale d Assurance Maladie des Travailleurs Salariés which insures 87% of the population. MS like other chronic diseases is one of the 30 long-term illnesses (Affections de Longue Durée, ALD). We analysed geographic variations in the prevalence and incidence of MS in France using the Bayesian approach.Total MS prevalence in France standardised for age was 94.7 per 100,000; 130.5 in women; 54.8 in men. The notification rate for MS (2000-2007) after age-standardisation according to the European population was 6.8 per 100,000; 9.8 in women and 3.7 in men. With a Bayesian approach, the prevalence of MS was higher in northeast and lower in the Paris area and on the Mediterranean coast. The notification rate was higher in northeast and lower on the Atlantic coast and in the Alps as well as on both sides of the Rhône River.The study of other chronic diseases for which ALD status was registered before MS revealed that comorbidities were rare, essentially represented by psychiatric diseases (40.2%) and diabetes (20.3%).This study is performed among a representative population using the same method throughout. The Bayesian approach which takes into account spatial heterogeneity and spatial autocorrelation did not confirm the existence of a clear gradient but only higher or lower areas of MS. The better knowledge of MS epidemiology will allow to venture hypothesis its etiological factors.DIJON-BU Doc.électronique (212319901) / SudocSudocFranceF

Epidémiologie de la sclérose en plaques en France

In Europe, France is located between high and low risk areas of Multiple Sclerosis (MS). We estimated the national prevalence of MS in France on 31st October 2004 and the incidence between 2000 and 2007 based on data from the ‘Caisse Nationale d’Assurance Maladie des Travailleurs Salariés’ which insures 87% of the population. MS like other chronic diseases is one of the 30 long-term illnesses (Affections de Longue Durée, ALD). We analysed geographic variations in the prevalence and incidence of MS in France using the Bayesian approach.Total MS prevalence in France standardised for age was 94.7 per 100,000; 130.5 in women; 54.8 in men. The notification rate for MS (2000-2007) after age-standardisation according to the European population was 6.8 per 100,000; 9.8 in women and 3.7 in men. With a Bayesian approach, the prevalence of MS was higher in northeast and lower in the Paris area and on the Mediterranean coast. The notification rate was higher in northeast and lower on the Atlantic coast and in the Alps as well as on both sides of the Rhône River.The study of other chronic diseases for which ALD status was registered before MS revealed that comorbidities were rare, essentially represented by psychiatric diseases (40.2%) and diabetes (20.3%).This study is performed among a representative population using the same method throughout. The Bayesian approach which takes into account spatial heterogeneity and spatial autocorrelation did not confirm the existence of a clear gradient but only higher or lower areas of MS. The better knowledge of MS epidemiology will allow to venture hypothesis its etiological factors.En Europe, la France est située entre des zones à haut et bas risque de Sclérose en Plaques (SEP).Nous avons estimé la prévalence de la SEP en France au 31 octobre 2004 et l’incidence entre 2000 et 2007 à partir des données de la Caisse Nationale d’Assurance Maladie des Travailleurs Salariés (CNAMTS) qui assure 87 % de la population. La SEP, comme d’autres maladies chroniques, fait partie des affections de longue durée (ALD). Les variations géographiques de la prévalence et de l’incidence ont été analysées par un modèle Bayesien.La prévalence standardisée sur l’âge était de 94,7 pour 100 000 ; 130,5 pour les femmes ; 54,8 pour les hommes. Le taux de notification de SEP (2000-2007) standardisé sur la population Européenne était de 6,8 pour 100 000 ; 9,8 parmi les femmes et 3,7 parmi les hommes. Avec le modèle Bayesien, la prévalence était plus forte au nord-est et plus faible dans la région parisienne et sur la Côte d’Azur. L’incidence était également plus forte au nord-est mais plus faible sur la côte atlantique et de part et d’autre du Rhône.A partir des autres ALD, les comorbidités survenant avant l’ALD SEP ont été étudiées. Elles étaient rares et essentiellement représentées par les troubles psychiatriques (40,2%) et le diabète (20,3%). Cette étude a été réalisée parmi une population représentative avec une seule et même méthodologie. Le modèle Bayesien prenant en compte l’hétérogénéité et l’auto-corrélation spatiales ne confirme pas l’existence d’un gradient net mais des zones à sur ou sous risque. La meilleure connaissance de l’épidémiologie de la SEP permettra d’avancer sur ses facteurs étiologiques

Epidemiology of Multiple Sclerosis en France

En Europe, la France est située entre des zones à haut et bas risque de Sclérose en Plaques (SEP).Nous avons estimé la prévalence de la SEP en France au 31 octobre 2004 et l’incidence entre 2000 et 2007 à partir des données de la Caisse Nationale d’Assurance Maladie des Travailleurs Salariés (CNAMTS) qui assure 87 % de la population. La SEP, comme d’autres maladies chroniques, fait partie des affections de longue durée (ALD). Les variations géographiques de la prévalence et de l’incidence ont été analysées par un modèle Bayesien.La prévalence standardisée sur l’âge était de 94,7 pour 100 000 ; 130,5 pour les femmes ; 54,8 pour les hommes. Le taux de notification de SEP (2000-2007) standardisé sur la population Européenne était de 6,8 pour 100 000 ; 9,8 parmi les femmes et 3,7 parmi les hommes. Avec le modèle Bayesien, la prévalence était plus forte au nord-est et plus faible dans la région parisienne et sur la Côte d’Azur. L’incidence était également plus forte au nord-est mais plus faible sur la côte atlantique et de part et d’autre du Rhône.A partir des autres ALD, les comorbidités survenant avant l’ALD SEP ont été étudiées. Elles étaient rares et essentiellement représentées par les troubles psychiatriques (40,2%) et le diabète (20,3%). Cette étude a été réalisée parmi une population représentative avec une seule et même méthodologie. Le modèle Bayesien prenant en compte l’hétérogénéité et l’auto-corrélation spatiales ne confirme pas l’existence d’un gradient net mais des zones à sur ou sous risque. La meilleure connaissance de l’épidémiologie de la SEP permettra d’avancer sur ses facteurs étiologiques.In Europe, France is located between high and low risk areas of Multiple Sclerosis (MS). We estimated the national prevalence of MS in France on 31st October 2004 and the incidence between 2000 and 2007 based on data from the ‘Caisse Nationale d’Assurance Maladie des Travailleurs Salariés’ which insures 87% of the population. MS like other chronic diseases is one of the 30 long-term illnesses (Affections de Longue Durée, ALD). We analysed geographic variations in the prevalence and incidence of MS in France using the Bayesian approach.Total MS prevalence in France standardised for age was 94.7 per 100,000; 130.5 in women; 54.8 in men. The notification rate for MS (2000-2007) after age-standardisation according to the European population was 6.8 per 100,000; 9.8 in women and 3.7 in men. With a Bayesian approach, the prevalence of MS was higher in northeast and lower in the Paris area and on the Mediterranean coast. The notification rate was higher in northeast and lower on the Atlantic coast and in the Alps as well as on both sides of the Rhône River.The study of other chronic diseases for which ALD status was registered before MS revealed that comorbidities were rare, essentially represented by psychiatric diseases (40.2%) and diabetes (20.3%).This study is performed among a representative population using the same method throughout. The Bayesian approach which takes into account spatial heterogeneity and spatial autocorrelation did not confirm the existence of a clear gradient but only higher or lower areas of MS. The better knowledge of MS epidemiology will allow to venture hypothesis its etiological factors

Détermination des facteurs prédictifs cliniques de réponse aux interférons bêta dans les scléroses en plaques rémittentes

DIJON-BU Médecine Pharmacie (212312103) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Un dépôt d’anneaux en schiste à Falaise « ZAC Expansia » (Calvados) ?

Fromont Nicolas, Hérard Agnès, Hérard Benjamin. Un dépôt d’anneaux en schiste à Falaise « ZAC Expansia » (Calvados) ?. In: Bulletin de la Société préhistorique française, tome 106, n°2, 2009. pp. 380-383

Epidemiology of multiple sclerosis

International audienceMultiple sclerosis (MS) is the most frequently seen demyelinating disease, with a prevalence that varies considerably, from high levels in North America and Europe (> 100/100,000 inhabitants) to low rates in Eastern Asia and sub-Saharan Africa (2/100,000 population). Knowledge of the geographical distribution of the disease and its survival data, and a better understanding of the natural history of the disease, have improved our understanding of the respective roles of endogenous and exogenous causes of MS. Concerning mortality, in a large French cohort of 27,603 patients, there was no difference between MS patients and controls in the first 20 years of the disease, although life expectancy was reduced by 6–7 years in MS patients. In 2004, the prevalence of MS in France was 94.7/100,000 population, according to data from the French National Health Insurance Agency for Salaried Workers (Caisse nationale d’assurance maladie des travailleurs Salariés [CNAM-TS]), which insures 87% of the French population. This prevalence was higher in the North and East of France. In several countries, including France, the gender ratio for MS incidence (women/men) went from 2/1 to 3/1 from the 1950s to the 2000s, but only for the relapsing–remitting form. As for risk factors of MS, the most pertinent environmental factors are infection with Epstein-Barr virus (EBV), especially if it arises after childhood and is symptomatic. The role of smoking in MS risk has been confirmed, but is modest. In contrast, vaccines, stress, traumatic events and allergies have not been identified as risk factors, while the involvement of vitamin D has yet to be confirmed. From a genetic point of view, the association between HLA-DRB1*15:01 and a high risk of MS has been known for decades. More recently, immunogenetic markers have been identified (IL2RA, IL7RA) and, in particular thanks to studies of genome-wide associations, more than 100 genetic variants have been reported. Most of these are involved in the immune response and often associated with other autoimmune diseases. Studies of the natural history of MS suggest it is a two-phase disease: in the first phase, inflammation is focal with flares; and in the second phase, disability progresses independently of focal inflammation. This has clear implications for therapy. Age may also be a key factor in the phenotype of the disease. In conclusion, France is a high-risk country for MS, but it only slightly reduces life expectancy. MS is a multifactorial disease and the implications of immunogenetics are major. Preventative approaches might be derived from knowledge of the risk factors and natural history of the disease (smoking, vitamin D

Interférences des traitements par biotine avec les immunodosages : il est temps de trouver une solution à long terme !

IF 0.908 (2017)Lettre à l'éditeur ("La Presse Médicale" vol. 47 n°1)https://www.sciencedirect.com/science/article/pii/S075549821730461X?via%3Dihu

Anti-Argonaute antibodies as a potential biomarker in NMOSD

Background and objectives: Neuromyelitis optica spectrum disorders (NMOSDs) are a group of diseases mainly characterised by recurrent optic neuritis and/or myelitis. Most cases are associated with a pathogenic antibody against aquaporin-4 (AQP4-Ab), while some patients display autoantibodies targeting the myelin oligodendrocyte glycoprotein (myelin oligodendrocyte glycoprotein antibodies (MOG-Abs)). Anti-Argonaute antibodies (Ago-Abs) were first described in patients with rheumatological conditions and were recently reported as a potential biomarker in patients with neurological disorders. The aims of the study were to investigate if Ago-Abs can be detected in NMOSD and to evaluate its clinical usefulness. Methods: Sera from patients prospectively referred to our centre with suspected NMOSD were tested for AQP4-Abs, MOG-Abs and Ago-Abs with cell-based assays. Results: The cohort included 104 prospective patients: 43 AQP4-Abs-positive cases, 34 MOG-Abs positive cases and 27 double-negative patients. Ago-Abs were detected in 7 of 104 patients (6.7%). Clinical data were available for six of seven patients. The median age at onset of patients with Ago-Abs was 37.5 [IQR 28.8-50.8]; five of six patients tested positive also for AQP4-Abs. Clinical presentation at onset was transverse myelitis in five patients, while one presented with diencephalic syndrome and experienced a transverse myelitis during follow-up. One case presented a concomitant polyradiculopathy. Median EDSS score at onset was 7.5 [IQR 4.8-8.4]; median follow-up was 40.3 months [IQR 8.3-64.7], and median EDSS score at last evaluation was 4.25 [IQR 1.9-5.5]. Conclusion: Ago-Abs are present in a subset of patients with NMOSD and, in some cases, represent the only biomarker of an autoimmune process. Their presence is associated with a myelitis phenotype and a severe disease course

Development of a sensitive method for Toxoplasma gondii oocyst extraction in soil.

UMR6249 Chrono-environnement Besançon USC INRAInternational audienceToxoplasmosis is a world-wide infection caused by Toxoplasma gondii. Oocysts disseminated in the environment by infected cats provide a major source of infection for humans and intermediate hosts. The level of soil contamination and the dynamics of this contamination are mostly unknown due to the lack of sensitivity of detection method. Our aim was to improve the detection of T. gondii oocysts in soil samples by comparing three extraction protocols (A, B and C) on unsporulated and sporulated oocysts of different strains and ages, and by testing the effect of sporulation and soil characteristics on oocyst recovery using the most efficient method. The oocyst recovery obtained using protocol C, in which the flotation solution was placed under the sample solution after the dispersion step, was at least ten-fold higher than protocols A and B, in which the sample was just filtered before flotation. The efficiency of protocol C, tested on five artificial soil matrices and four natural soils inoculated with oocysts, was lowest in soils with high proportions of sand. We recommend the protocol C for field investigations, and we advise that results should be interpreted with caution, considering the effect of soil characteristics, especially sand content, on oocyst recovery